Your Health, We Care
Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
from FDA，2024.01
During treatment with Selumetinib, in addition to its expected therapeutic effec···【more】
Release date：2026-03-10Recommended：6
Koselugo is suitable for treating children aged 2 years and above with type 1 ne···【more】
Release date：2026-01-05Recommended：16
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as···【more】
Release date：2024-08-22Recommended：231
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that i···【more】
Release date：2024-08-22Recommended：232
Koselugois a small molecule drug inhibitor targeting the MEK signaling pathway, ···【more】
Release date：2024-08-21Recommended：206
